XYZ Robotics develops AI-enabled robotic perception and manipulation technology for logistics and manufacturing automation. The company develops autonomous robotic solutions for put wall sorting and goods-to-person picking. Its robot sorts unorganized, random warehouse goods into groups of customer orders. The solution embodies its strength in deep learning and robotics.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Regenerative Bio is a pioneering biotechnology company focused on anti-aging solutions through the integration of artificial intelligence and advanced computing technologies. The company is dedicated to researching and developing ingredients, formulations, and therapies aimed at mitigating the effects of aging and enhancing overall health. By leveraging AI, quantum physics, and high-throughput preparation methods, Regenerative Bio seeks to improve cellular health and energy metabolism, ultimately promoting longer, healthier lives. Their innovative approach combines pharmaceutical technology with biological research, addressing age-related health issues and contributing to the field of longevity science.
Almond Fintech is a developer of a cross-border payment platform that facilitates remittances and payments across various providers and borders. The company's platform offers currency exchange services and ensures interoperability between mobile wallets and financial services. This enables individuals and businesses to send and receive money using their existing wallets, streamlining the process of cross-border transactions. By focusing on enhancing mobile financial services, Almond Fintech aims to simplify and improve the user experience for both personal and business financial activities.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
DeepCure Inc. offers drugs discovery services using artificial intelligence technology. Its products include De-novo Lead Discovery, Artificial Intelligence-driven Lead Optimization, and MoIDB. De-novo Lead Discovery uses artificial intelligence algorithms to analyze drug candidates from virtual library. Artificial Intelligence-driven Lead Optimization identifies optimization steps to improve the development of drugs. MolDB is designed to maximize scale, diversity, and synthesizability of chemical search space. DeepCure Inc. develops new drug through molecular feature extraction, MoIDB, artificial intelligence predictive modeling and feedback loop. The company was founded in 2018 and is based in Boston, Massachusetts.
Robigo is a biopesticide engineering the plant microbiome to reduce disease in crops.
Signet Therapeutics
Seed Round in 2021
Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.
XYZ Robotics develops AI-enabled robotic perception and manipulation technology for logistics and manufacturing automation. The company develops autonomous robotic solutions for put wall sorting and goods-to-person picking. Its robot sorts unorganized, random warehouse goods into groups of customer orders. The solution embodies its strength in deep learning and robotics.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Fount Bio is a life science company that applies proprietary advances in glycopolymer research for skin health. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts, United States.
Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to developing therapies for diseases associated with mitochondrial dysfunction, which includes both rare genetic disorders and common age-related conditions. The company's lead product candidate, Elamipretide, aims to address these health issues, while additional candidates like SBT-20 and SBT-272 are being explored for their potential benefits in stabilizing mitochondrial function and treating neurodegenerative diseases, respectively. Founded in 2006 and based in George Town, Cayman Islands, Stealth BioTherapeutics collaborates with patients and advocacy groups to deepen its understanding of the challenges faced by those with mitochondrial diseases and to raise awareness of their therapeutic programs.
Coin Metrics Inc. is an online publisher specializing in blockchain and cryptocurrency data, offering a range of market and network analytics to various industries. Founded in 2017 and based in Cambridge, Massachusetts, the company provides several key products, including the CM Network Data Pro, which delivers historical crypto network data in a detailed format for institutional clients. Additionally, Coin Metrics offers the CM Market Data Feed, a standardized solution for trade, candle, and order book data from multiple exchanges, and CM Reference Rates, which provides fixed pricing for various assets quoted in U.S. dollars. By focusing on transparent and actionable data, Coin Metrics enables stakeholders to better understand and utilize public crypto networks.
Catalant Technologies, Inc. is a Boston-based software company that specializes in providing solutions for strategy execution to global enterprises. Founded in 2013 and formerly known as HourlyNerd, the company offers a platform that assists organizations in transforming their strategic objectives into actionable plans. Catalant's software enables businesses to align work, access both internal and external resources, collaborate effectively, and measure the value of their efforts, facilitating faster execution of mission-critical projects. The platform connects enterprises with a global network of over 65,000 experts and more than 27,000 boutique firms, providing a streamlined approach to sourcing expertise on demand. By leveraging best-in-class tools for talent management, Catalant helps clients improve efficiency and effectiveness in achieving their strategic goals.
Stavvy is a modern lending experience designed to connect lenders with their title, settlement, and appraisal vendors. The Stavvy Connect is a fully-integrated, digital mortgage vendor platform that allows mortgage banking professionals to seamlessly and securely communicate and access vendor data & deliverables without fragmentation or exposure to unnecessary risk. The Stavvy Notarize empowers title agents, lawyers, notaries and other real estate professionals to leverage the power of web conference technology to conduct virtual closings and meetings in real-time.
XYZ Robotics develops AI-enabled robotic perception and manipulation technology for logistics and manufacturing automation. The company develops autonomous robotic solutions for put wall sorting and goods-to-person picking. Its robot sorts unorganized, random warehouse goods into groups of customer orders. The solution embodies its strength in deep learning and robotics.
Vesigen, Inc. is a biotechnology company focused on developing innovative therapeutic products that utilize extracellular vesicle delivery technology to target intracellular sites. Founded in 2020 and based in Cambridge, Massachusetts, the company employs its proprietary ARMMs technology to facilitate the direct delivery of various payloads, including RNAs, proteins, and gene-editing complexes, into the cytoplasm of target cells. This approach aims to overcome the challenges associated with intracellular drug delivery, thereby broadening the range of potential druggable targets and enabling the creation of novel treatments for various diseases. Vesigen's mission is to address unmet medical needs through its advanced therapeutic solutions.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.
Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to developing therapies for diseases associated with mitochondrial dysfunction, which includes both rare genetic disorders and common age-related conditions. The company's lead product candidate, Elamipretide, aims to address these health issues, while additional candidates like SBT-20 and SBT-272 are being explored for their potential benefits in stabilizing mitochondrial function and treating neurodegenerative diseases, respectively. Founded in 2006 and based in George Town, Cayman Islands, Stealth BioTherapeutics collaborates with patients and advocacy groups to deepen its understanding of the challenges faced by those with mitochondrial diseases and to raise awareness of their therapeutic programs.
CairnSurgical is developing innovative patient-specific tools to guide surgical interventions for patients with cancer.
XYZ Robotics develops AI-enabled robotic perception and manipulation technology for logistics and manufacturing automation. The company develops autonomous robotic solutions for put wall sorting and goods-to-person picking. Its robot sorts unorganized, random warehouse goods into groups of customer orders. The solution embodies its strength in deep learning and robotics.
CollegeVine provides mentorship, college applications guidance, college essay assistance, tutoring, and test preparation consulting services. The company was formerly known as Admissions Hero LLC and changed its name to CollegeVine in August 2016. CollegeVine was founded in 2013 and is based in Cambridge, Massachusetts.
Apic Bio, Inc. is a biotechnology company focused on developing gene therapies for rare and undertreated neurological and liver diseases. Established in 2017 and based in Cambridge, Massachusetts, the company is particularly engaged in treating alpha-1 antitrypsin deficiency. Its lead product, APB-101, utilizes a unique gene therapy platform that employs a dual-function vector to target the liver, silencing the Z-AAT protein while augmenting the M-AAT protein. Apic Bio aims to address the complexities associated with rare diseases through innovative therapeutic approaches.
Desora, Inc. is a startup based in Cambridge, Massachusetts, founded by Harvard graduates and faculty in 2016. The company specializes in designing and manufacturing smart cooking appliances, primarily focusing on innovative grilling technology. Its flagship product is a smart barbecue device that can be controlled via a mobile application, allowing users to easily start, stop, and monitor the cooking process. This appliance features a unique design that creates cyclonic smoke spirals to ensure even cooking and eliminate hot spots, making it accessible for novice cooks to achieve exceptional barbecue results. Desora's commitment to combining rigorous science with culinary arts aims to enhance the cooking experience and promote enjoyment in home cooking. The company values diversity and welcomes applications from individuals of all backgrounds.
CollegeVine provides mentorship, college applications guidance, college essay assistance, tutoring, and test preparation consulting services. The company was formerly known as Admissions Hero LLC and changed its name to CollegeVine in August 2016. CollegeVine was founded in 2013 and is based in Cambridge, Massachusetts.
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.
CollegeVine provides mentorship, college applications guidance, college essay assistance, tutoring, and test preparation consulting services. The company was formerly known as Admissions Hero LLC and changed its name to CollegeVine in August 2016. CollegeVine was founded in 2013 and is based in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Flyp, Inc. is a telecommunications company based in the United States that aims to enhance the global consumer communications experience. It offers a proprietary platform that allows users to manage multiple phone numbers on a single device while providing high-quality voice and text communications, both in-network and out-of-network. Notably, Flyp serves international customers by offering a unique solution that provides a local US phone number, enabling mobile users to make free calls and send texts to and from any US phone number. This innovative approach allows users to consolidate their mobile communications into one streamlined application, facilitating hassle-free interactions.
Vigeo Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic agents intended to treat an advanced malignant tumor that can effectively treat multiple types of cancer and improve the lives of patients. The company building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). They plan to commence multiple combination studies to evaluate VT1021 in combination with chemotherapies and/or anti-PD-1 antibodies. Vigeo Therapeutics was established in 2011 and is headquartered in Cambridge, Massachusetts, United States.
Synchroneuron Inc. is a biopharmaceutical company focused on developing therapies for tardive dyskinesia and other neuropsychiatric disorders. Its lead candidate, SNC-102, is a sustained-release formulation of acamprosate calcium that aims to enhance pharmacokinetic properties compared to existing formulations. SNC-102 is designed to address tardive dyskinesia by modulating both excitatory and inhibitory neurotransmission in the neural circuits responsible for involuntary movements. The drug is currently undergoing evaluation in phase 2 trials for tardive dyskinesia and Tourette syndrome, as well as in phase 1 trials for combat-related posttraumatic stress disorder. Founded in 2011 and based in Duxbury, Massachusetts, Synchroneuron was previously known as Eukinetix, Inc.
BiddingForGood is a charitable e-commerce company that connects fundraisers, shoppers and businesses. Online auctions powered by BiddingForGood have generated over $110 million for nonprofit organizations and schools. Many of the top private and public schools and nonprofits in the country use the BiddingForGood platform.
The 220,000+ shoppers in our Bidder Community are buying unique and valuable items across our many auctions - all to support the important organizations and causes they care about.
Businesses are unlocking new sources of value while managing their philanthropic outreach and impact, and are discovering unique, powerful ways to reach new customers within our community.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
Synchroneuron Inc. is a biopharmaceutical company focused on developing therapies for tardive dyskinesia and other neuropsychiatric disorders. Its lead candidate, SNC-102, is a sustained-release formulation of acamprosate calcium that aims to enhance pharmacokinetic properties compared to existing formulations. SNC-102 is designed to address tardive dyskinesia by modulating both excitatory and inhibitory neurotransmission in the neural circuits responsible for involuntary movements. The drug is currently undergoing evaluation in phase 2 trials for tardive dyskinesia and Tourette syndrome, as well as in phase 1 trials for combat-related posttraumatic stress disorder. Founded in 2011 and based in Duxbury, Massachusetts, Synchroneuron was previously known as Eukinetix, Inc.
Clean Membranes, Inc. produces anti-fouling membranes for various water treatment applications. It offers products for the desalination of seawater and brackish water; purification of surface and well water; municipal and industrial wastewater treatment; pharmaceutical and food industry; oil and gas extraction; industrial and pharmaceutical market; seawater desalination; and producing potable water from brackish water applications. The company was incorporated in 2008 and is based in Lexington, Massachusetts.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
ProterixBio, Inc. specializes in developing disease management platforms aimed at improving patient outcomes in chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company utilizes its proprietary ViBE platform and Acoustic Membrane MicroParticle (AMMP) assays to facilitate the precise analysis of proteins in various biological samples, including blood and sputum. The AMMP technology employs a non-optical, homogeneous assay approach, which enhances the sensitivity and specificity of traditional reagents through the integration of biological capture strategies and advanced acoustic sensors. By providing real-time biological assessments of a patient's disease state, ProterixBio's products support healthcare providers in managing chronic conditions more effectively, reducing the need for hospitalizations, and ultimately lowering healthcare costs. Founded in 2002 and based in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in May 2016.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
ThingMagic is a leading developer of radio frequency identification (RFID) technology, with broad experience in applying RFID in a wide range of industrial and consumer applications. ThingMagic's customers include some of the world's largest retailers, consumer companies, automotive firms, manufacturers and industrial automation firms. ThingMagic products include fixed and embedded RFID readers and antennas, embedded and OEM RFID technology, and professional services to facilitate the OEM integration of RFID into a wide range of industrial and consumer products.
Serica Technologies, Inc., a medical device company, develops silk-based biomaterial platforms that are used in tissue repair caused by disease, trauma, or aging. The company offers SeriGel, a long-term bioresorbable silk hydrogel that is used in plastic and reconstructive surgery, and drug delivery; and SeriFascia surgical scaffold implant, which enables the reestablishment of functional collagen sheet-like tissue that has diminished as a result of either surgery or aging. It also provides SeriACL graft, a biocompatible and biodegradable ligament graft that is used for anterior cruciate ligament (ACL) repair; SeriCuff scaffold, which is used in rotator cuff tendon repair; and SeriScaffold surgical mesh that is used to repair and remodel damaged connective tissues. The company's products are used in orthopedics and sports medicine, aesthetic and reconstructive plastic surgery, and multiple additional structural tissue repair applications. Serica Technologies was formerly known as Tissue Regeneration, Inc. and changed its name to Serica Technologies, Inc. in 2006. The company was founded in 1998 and is based in Medford, Massachusetts. As of February 4, 2010, Serica Technologies, Inc. operates as a subsidiary of Allergan Inc.
ThingMagic is a leading developer of radio frequency identification (RFID) technology, with broad experience in applying RFID in a wide range of industrial and consumer applications. ThingMagic's customers include some of the world's largest retailers, consumer companies, automotive firms, manufacturers and industrial automation firms. ThingMagic products include fixed and embedded RFID readers and antennas, embedded and OEM RFID technology, and professional services to facilitate the OEM integration of RFID into a wide range of industrial and consumer products.
BiddingForGood is a charitable e-commerce company that connects fundraisers, shoppers and businesses. Online auctions powered by BiddingForGood have generated over $110 million for nonprofit organizations and schools. Many of the top private and public schools and nonprofits in the country use the BiddingForGood platform.
The 220,000+ shoppers in our Bidder Community are buying unique and valuable items across our many auctions - all to support the important organizations and causes they care about.
Businesses are unlocking new sources of value while managing their philanthropic outreach and impact, and are discovering unique, powerful ways to reach new customers within our community.
ThingMagic is a leading developer of radio frequency identification (RFID) technology, with broad experience in applying RFID in a wide range of industrial and consumer applications. ThingMagic's customers include some of the world's largest retailers, consumer companies, automotive firms, manufacturers and industrial automation firms. ThingMagic products include fixed and embedded RFID readers and antennas, embedded and OEM RFID technology, and professional services to facilitate the OEM integration of RFID into a wide range of industrial and consumer products.